ImmunityBio, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(a)Adoption and Termination (including Modification) of Rule 10b5-1 and Certain Other Trading Arrangements by Directors and Officers
On September 15, 2026, Michael Blaszyk, anindependent member of our Board of Directors, adopted a written trading plan for the potential sale of up to 958,265 shares of our common stock. The plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan remains in effect until December 31, 2027, or earlier upon the completion of all sales thereunder.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.